The article discusses the role of anti-factor H antibodies in the pathogenesis of aHUS, especially in cases linked to drug-induced immune dysregulation. Implications for therapy: Recommends treatments, such as plasmapheresis and complement inhibitors, for managing antibody-related cases. Here, CFH is linked to atypical hemolytic-uremic syndrome.